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First-in-Class Anti-immunoglobulin–like Transcript 4
Myeloid-Speciﬁc Antibody MK-4830 Abrogates a PD-1
Resistance Mechanism in Patients with Advanced Solid
Tumors
Lillian L. Siu1, Ding Wang2, John Hilton3, Ravit Geva4, Drew Rasco5, Ruth Perets6,7, Anson K. Abraham8,
Douglas C. Wilson9, Julia F. Markensohn8, Jared Lunceford8, Leah Suttner8, Shabana Siddiqi8,
Rachel A. Altura8, and Corinne Maurice-Dror10

ABSTRACT

◥

Purpose: In this ﬁrst-in-human study (NCT03564691) in
advanced solid tumors, we investigated a novel ﬁrst-in-class human
IgG4 monoclonal antibody targeting the immunoglobulin-like
transcript 4 (ILT4) receptor, MK-4830, as monotherapy and in
combination with pembrolizumab.
Experimental Design: Patients with histologically/cytologically
conﬁrmed advanced solid tumors, measurable disease by RECIST
v1.1, and evaluable baseline tumor sample received escalating doses
of intravenous MK-4830 every 3 weeks as monotherapy (parts A
and B) and in combination with pembrolizumab (part C). Safety
and tolerability were the primary objectives. Pharmacokinetics,
objective response rate per RECIST v1.1, and molecular biomarkers
were also evaluated.
Results: Of 84 patients, 50 received monotherapy and 34
received combination therapy. No dose-limiting toxicities were
observed; maximum tolerated dose was not reached. MK-4830
showed dose-related target engagement. Eleven of 34 patients in

the dose-escalation phase who received combination therapy
achieved objective responses; 5 previously had progressive disease
on anti–PD-1/PD-L1 therapies. Exploratory evaluation of the
association between response and pretreatment gene expression
related to interferon-gamma signaling in tumors suggested higher
sensitivity to T-cell inﬂammation with combination therapy than
historically expected with pembrolizumab monotherapy, with
greater response at more moderate levels of inﬂammation.
Conclusions: This ﬁrst-in-class MK-4830 antibody dosed as
monotherapy and in combination with pembrolizumab was well
tolerated with no unexpected toxicities, and demonstrated doserelated evidence of target engagement and antitumor activity.
Inﬂammation intrinsic to the ILT4 mechanism may be facilitated
by alleviating the myeloid-suppressive components of the tumor
microenvironment, supporting the target of ILT4 as a potential
novel immunotherapy in combination with an anti–PD-1/PD-L1
agent.
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The development of immune checkpoint inhibitors, including
monoclonal antibodies against programmed death 1 (PD-1) or its
ligand, programmed death ligand 1 (PD-L1), has improved patient
outcomes in those with advanced malignancies; however, many
patients do not respond to these therapies or they acquire resistance
to them (1). Combining immunotherapies that target distinct mechanisms of immunosuppression may improve outcomes or overcome
resistance (1, 2). In addition to the PD-1/PD-L1 axis, which suppresses
antitumor effector T-cell responses (3, 4), myeloid-derived suppressor
cells (MDSC) represent another major axis of immunosuppression (5)
and are associated with poor prognosis in patients with cancer (6).
MDSCs dampen T-cell activation, proliferation, and effector responses
through numerous mechanisms, including, but not limited to, cytokine production, cell surface receptor signaling, reactive oxygen
species production, nutrient deprivation, and regulatory T-cell recruitment (7). Given that MDSCs are a common constituent of the tumor
microenvironment and because of their diverse arsenal of suppressive
mechanisms, MDSCs are considered a prime target for therapeutic
intervention, especially in combination with T-cell–targeted immunotherapy. Several novel therapeutics targeting one or more of these
mechanisms have recently been explored in early clinical trials,
including molecules targeting colony stimulating factor 1 receptor,
CXC chemokine receptors 1/2, adenosine receptors, and class 1 histone
deacetylases (8).
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Translational Relevance
MK-4830 plus pembrolizumab was well tolerated and elicited
antitumor activity in patients with pretreated advanced solid
tumors, including those whose disease previously progressed on
immunotherapy. Analysis of tumor response by pretreatment
tumor expression of genes related to T-cell inﬂammation supports
the potential for a new mechanism to treat anti–PD-1/PD-L1
resistance. The intriguing data from this study support the further
development of MK-4830 in combination with pembrolizumab for
patients with advanced solid tumors and the continued investigation into the T-cell and myeloid expression signatures.

Immunoglobulin-like transcript 4 (ILT4) receptor—otherwise
known as leukocyte immunoglobulin-like receptor B2 (LILRB2)—is
an immunosuppressive member of the immunoglobulin-like transcript (ILT) family that is commonly expressed by many myeloid
lineages, including monocytes, macrophages, granulocytes, and dendritic cells (9–12). In the tumor microenvironment, ILT4 is expressed
by cells with a phenotype associated with monocytic MDSCs
(mMDSC) and granulocytic MDSCs (gMDSC; ref. 13). The prototypical ligand for ILT4 is human leukocyte antigen G (HLA-G), a
nonclassical MHC class I molecule expressed by a wide range of
tumors; its expression is correlated with poor prognosis (10, 14, 15).
Several other ILT4 ligands, including classical human leukocyte antigens (HLA) and angiopoietin-like proteins (12), also may be relevant
in driving ILT4-mediated immunosuppression in the tumor microenvironment. Emerging data show that ILT4 antagonism in tumorassociated macrophages (TAM) induces a more proinﬂammatory
state, one that is marked by a shift from the M2-phenotype toward
an M1-phenotype (12, 16). Reprogramming TAMs or MDSCs or both

to a proinﬂammatory state may be more advantageous than targeting
these cells for depletion because the resultant proinﬂammatory
response from ILT4 inhibition may better stimulate the antitumor
T-cell response, particularly in combination with PD-1/PD-L1
blockade (17).
MK-4830 is a fully human monoclonal antibody of the immunoglobulin G4 subclass that speciﬁcally binds to ILT4 and blocks its
interaction with HLA-G and other ligands (Fig. 1; ref. 18). Preclinical
data demonstrated that MK-4830 binds to monocytes and granulocytes in the peripheral blood of healthy volunteers and patients with
cancer. In a humanized mouse model of cancer, MK-4830 treatment
induced signiﬁcant inhibition of tumor growth (18).
Previous studies have ﬁrmly established several tumor-associated
biomarkers, including PD-L1, tumor mutational burden (TMB), and
microsatellite instability (MSI), that associate with response to the
anti–PD-1 antibody pembrolizumab, leading to a more comprehensive and selective treatment paradigm (19). An IFNg-related, 18-gene,
T-cell–inﬂamed gene expression proﬁle (TcellinfGEP) signature has
also been shown to be positively associated with response to pembrolizumab monotherapy in several tumor types (20). Large external
databases such as The Cancer Genome Atlas and Merck-Mofﬁtt were
used to identify replicable consensus RNA expression signatures
intended to be ﬁt-for-purpose signatures representative of canonical
pathways associated with tumor biology and tumor microenvironment elements, including a signature related to mMDSCs (21). The
mMDSC signature score, when evaluated in joint models with the
TcellinfGEP in a large pan-tumor analysis of patients given pembrolizumab monotherapy (N ¼ 1,118), showed a modest but statistically
signiﬁcant negative association with objective response, providing
clinical evidence that the mMDSC–suppressor cell axis may be a
resistance mechanism for pembrolizumab monotherapy (21).
Here, we report efﬁcacy and safety data from the ﬁrst-in-human
phase I trial of MK-4830 as monotherapy and in combination with
Figure 1.
Proposed mechanism of action of MK4830. ILT4, immunoglobulin-like transcript 4; PD-1, programmed death 1.
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pembrolizumab in patients with advanced solid tumors. Although the
sample size was limited, descriptive evaluation of key pembrolizumab
monotherapy biomarkers in the context of combination therapy with
MK-4830 is provided because it may be relevant to interpreting the
evidence for ameliorating anti–PD-1/PD-L1 resistance in the combination therapy setting.

Materials and Methods
Study design
In this multicenter, open-label, ﬁrst-in-human, phase I trial,
patients were assigned to receive MK-4830 as monotherapy (parts
A and B) or in combination with pembrolizumab (part C; ClinicalTrials.gov, NCT03564691). Patients whose disease progressed on
monotherapy were eligible to cross over to combination therapy
following clinical or radiographical evaluation. This study was conducted in accordance with Good Clinical Practice Guidelines and the
Declaration of Helsinki; the protocol (4830–001–03) was approved by
the institutional review boards or ethics committees of all participating
sites. All patients provided written informed consent to participate
before enrollment.
Patient population
Patients (age ≥18 years) had histologically or cytologically conﬁrmed metastatic solid tumors for which no available therapy could
convey clinical beneﬁt (previous anti–PD-1/PD-L1 therapy was permitted), measurable disease per Response Evaluation Criteria in Solid
Tumors version 1.1 (RECIST v1.1), Eastern Cooperative Oncology
Group performance status of 0 or 1, evaluable baseline tumor sample
(archived or newly collected), and adequate organ function. Key
exclusion criteria included chemotherapy, radiotherapy, or biological
anticancer therapy ≤4 weeks before the ﬁrst dose, discontinuation of
any previous immunotherapy regimen because of an immune-related
adverse event (AE), previous treatment with another agent targeting
ILT4 or HLA-G, chronic systemic steroid therapy (the exception was
oral physiological replacements), known untreated central nervous
system metastasis or carcinomatous meningitis, and active autoimmune disease.
Treatment
MK-4830 was administered intravenously at a starting dose of 3 mg
and subsequent dose escalation to a maximum proposed dose of
1,600 mg every 3 weeks (Q3W). Given the potential for MK-4830 to
activate the immune system and the limitations of standard toxicology
studies to model these effects in the preclinical setting, a conservative
starting dose was chosen to ensure safety. The 3 mg starting dose of
MK-4830 was determined on the basis of integration of the data
obtained from in vitro studies evaluating MK-4830 binding to granulocytes and monocytes obtained from healthy volunteers and patients
with cancer (data not shown) and on nonclinical pharmacokinetics
and safety and toxicology studies in nonhuman primates. Emphasis
was placed on the in vitro receptor-binding data because of the lack of
target homology, orthologous protein expression, and cross-reactivity
of MK-4830 for ILT4 in rodents and nonhuman primates. The
maximum proposed dose of 1,600 mg was projected to provide
pharmacokinetic exposures in the micromolar range. The highest
dose of MK-4830 was expected to provide >90% target receptor
occupancy (RO) based on receptor-binding afﬁnity and was to be
conﬁrmed by measuring blood RO. Part A of the dose-escalation phase
(MK-4830 monotherapy) followed an accelerated titration design
(ATD) with 1 to 3 patients treated per cohort with an approximately
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3-fold increase between MK-4830 dose levels. The starting dose for
part B (MK-4830 monotherapy) was based on safety criteria [doselimiting toxicity (DLT) or grade ≥2 toxicity] or ≥75% ILT4 RO in
peripheral blood mononuclear cells demonstrated at any dose level in
part A. Part B of the dose-escalation phase continued using a modiﬁed
toxicity probability interval (mTPI) design to identify the maximum
tolerated dose (MTD) or the maximum-administered dose (MAD) of
MK-4830 monotherapy. Enrollment in part C (combination therapy
with MK-4830 plus pembrolizumab 200 mg Q3W) was initiated after
the ﬁrst 2 doses in part B were completed. Part C of the dose-escalation
phase used the mTPI method to determine the MTD or MAD of MK4830 in combination with pembrolizumab. Treatment continued until
progressive disease (PD), unacceptable AEs, intercurrent illness,
investigator/patient decision to withdraw, or 2 years of treatment.
Study outcomes
The primary objective of the dose-escalation phase was to characterize the safety and tolerability of MK-4830 as monotherapy and in
combination with pembrolizumab. The secondary objective was to
evaluate pharmacokinetic parameters of MK-4830 when administered
alone or with pembrolizumab. Tertiary objectives included evaluation
or identiﬁcation of the following: circulating anti–MK-4830 and antipembrolizumab antibodies; pharmacokinetics of pembrolizumab
administered in combination with MK-4830; objective response rate
(ORR) as determined by RECIST v1.1 and immune-related RECIST
per investigator (22); and molecular (genomic, metabolic, proteomic,
and/or transcriptomic) biomarkers potentially indicative of clinical
response or resistance, safety, pharmacodynamic activity, or mechanism of action of MK-4830 as monotherapy and in combination with
pembrolizumab. Disease control rate (DCR)—deﬁned as complete
response (CR), partial response (PR), or stable disease (SD) with
progression-free survival (PFS) duration of ≥6 months—was an
unspeciﬁed aspect of the analysis.
Safety assessments and imaging
The DLT evaluation period for the monotherapy and combination
groups encompassed events that occurred within the ﬁrst 3 weeks of
cycle 1, day 1. Dose ﬁnding for parts B and C followed the mTPI design,
with a target DLT rate of 30%. Safety was assessed by review of AEs and
serious AEs during the study and for 30 days after the last dose if the
patient transitioned to a new anticancer therapy or 90 days after the last
dose if the patient remained on study. For patients initially assigned to
monotherapy, AEs were recorded in the monotherapy group if they
occurred while the patient was receiving monotherapy and in the
combination therapy group if they occurred after the patient crossed
over to combination therapy. AE severity was graded according to the
Common Terminology Criteria for Adverse Events version 4.0. Tumor
imaging using CT or MRI was performed every 9 weeks until conﬁrmed PD, start of new anticancer therapy, withdrawal of consent,
death, or end of study.
Pharmacokinetics, anti-drug antibodies, and target
engagement
Serum concentrations of MK-4830 and pembrolizumab were used
to derive pharmacokinetic parameters of MK-4830 alone and with
pembrolizumab. Blood samples were collected to evaluate levels of
circulating anti-drug antibodies (ADA) and to perform pharmacodynamic RO analysis. RO of ILT4 was measured on circulating myeloid
cells before and after the administration of MK-4830. Brieﬂy, wholeblood and fresh tumor biopsy samples for ILT4 RO were assessed using
ﬁt-for-purpose validated ﬂow cytometry assays to support exploratory
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biomarker endpoints. A dual detection method was used to measure
unoccupied and total ILT4 on the cell surfaces of representative
myeloid cell types before or after MK-4830 administration or at both
time points. In blood, CD45þ/Lin1/CD11bþ/CD33þ/HLADRþexpressing monocytes were assessed, whereas in fresh tumor samples,
only viable CD45þ/Lin1/CD11bþ/CD33þ-expressing monocytes
were assessed because of the variable sample quality.
Biomarker assessments
PD-L1, TMB, TcellinfGEP, and myeloid-speciﬁc biomarkers were
assessed using archival or newly obtained tumor samples from all
patients in the combination group of the study.
PD-L1 protein expression was assessed by immunohistochemistry
(IHC) using PD-L1 22C3 IHC pharmDx (Agilent) performed at
Interpace Pharma Solutions.
TMB was assessed by DNA extracted from formalin-ﬁxed parafﬁn-embedded (FFPE) tissue using the Qiagen FFPE kit. DNA
fragmentation was performed using the Covaris M220 focusedultrasonicator with the settings of 75W for peak incident power,
25% as duty factor, 1,000 for cycles per burst, and a treatment time
of 6 minutes per sample at 40 C. For the TruSight Oncology 500
(TSO500) next-generation sequencing (NGS) library preparation,
40 to 50 mg FFPE DNA per sample was used. Library preparation
was performed manually in accordance with the manufacturer’s
protocol, with 24 samples per batch. NGS was performed on a
NextSeq 550 (Illumina) instrument with 8 libraries per sequencing
run. TSO500-TMB was reported using the TSO500 Local App
version 1 (Illumina). The manufacturer’s quality control criteria
were used to determine whether a result was valid, including NGS
library concentration of ≥1 ng/mL, median insert size of ≥70 base
pairs, median exon coverage of ≥50 count, and percentage of exons
with coverage ≥50 count of ≥90%.
TcellinfGEP and the mMDSC signatures were assessed by RNA
extracted from FFPE pretreatment tumor samples using the High Pure
FFPE RNA Isolation Kit (Roche) according to the manufacturer’s
protocol. RNA sequencing was used to measure the 18-gene
TcellinfGEP and the 218 genes of the mMDSC signature. Input sample
data were generated using the HiSeq 4000 and the TruSeq RNA Access
Library Prep method (Illumina). Gene-level fragments per kilobase
million (FPKM) values were generated in Omicsoft Array Studio v11.0
(Qiagen) according to the established RNA sequencing pipeline.
Omicsoft sequence aligner as alignment algorithm, Human.B37.3 as
alignment reference, and Ensembl.R75 as gene model were used.
FPKM values were then converted to log10(0.01 þ FPKM), and each
sample was normalized by subtracting the 75th percentile evaluated
over probes annotated as protein coding and assigned to chromosomes
1:22, X, and Y. TcellinfGEP score was calculated according to the
published formula as weighted sum over 18 genes using normalized
values for the 18 genes and previously published 18-gene coefﬁcients as
weights (20). Note that the TcellinfGEP is calculated as a weighted
average of its member genes, whereas the mMDSC signature score is a
simple average. Expression of myeloid-speciﬁc biomarkers, mMDSC
signature score, LILRB2 levels, and HLA-G were also evaluated. As
previously described (21), mMDSC signature scores are analyzed by
adjusting the data for the TcellinfGEP relative to the clinical outcome to
ensure the score is independent of the TcellinfGEP, which is in line with
ﬁndings for the mMDSC signature score as a negatively associated
factor in joint regression models with the TcellinfGEP (21). When
evaluating patterns of clinical response in the present study, parallel
use of the mMDSC signature score was analyzed by adjusting for the
TcellinfGEP by simple linear regression of the expression levels of
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mMDSC signature scores on the TcellinfGEP and calculating the
residual levels of mMDSC; this evaluates whether these putatively
suppressive myeloid-related factors are higher or lower than expectations based on TcellinfGEP. The same approach was used for
LILRB2 and HLA-G when comparing levels for responders and
nonresponders.
Serum cytokines, including IFNg, IL1b, IL2, IL4, IL6, IL8, IL10,
IL12p70, IL-13, and TNFa, were measured by ELISA. Flow cytometry
was also used to quantify circulating levels of monocytes, neutrophils,
mMDSCs, polymorphonuclear or granulocytic (PMN)-MDSCs, and
early-stage MDSCs as well as T-cell activation. Baseline expression
levels of HLA-A, HLA-B, HLA-C, HLA-F, and HLA-G were evaluated
in patient tumor samples by RNA sequencing.
Statistical analysis
Safety was evaluated in all patients who received ≥1 dose of study
treatment (all-patients-as-treated population), with patients grouped
according to the treatment received. The DLT-evaluable population
comprised patients who experienced a DLT during the ﬁrst cycle and
those who completed the ﬁrst cycle of treatment without a DLT.
Prespeciﬁed DLTs included the following: (i) grade 4 nonhematological toxicity (nonlaboratory); (ii) grade 4 hematological toxicity
lasting ≥7 days: grade 4 thrombocytopenia of any duration and/or
grade 3 thrombocytopenia associated with clinically signiﬁcant bleeding; (iii) any nonhematological AE grade ≥3 in severity (exceptions:
grade 3 fatigue lasting ≤3 days; grade 3 diarrhea, nausea, or vomiting
without use of antiemetics or antidiarrheals per standard of care; and
grade 3 rash without the use of corticosteroids or anti-inﬂammatory
agents per standard of care); (iv) any grade 3 or grade 4 ALT (alanine
aminotransferase), AST (aspartate aminotransferase), or bilirubin
laboratory values [exception: If AST or ALT was grade 2 at baseline
(as in patients with liver metastases), then a DLT was deﬁned as >2
above baseline]; (v) any other nonhematological laboratory value if
clinically signiﬁcant medical intervention was required to treat the
patient, or if the abnormality led to hospitalization, persisted for
>1 week, or resulted in a drug-induced liver injury (exceptions:
clinically nonsigniﬁcant, treatable, or reversible laboratory abnormality, including in alkaline phosphatase, gamma glutamyl transferase, or
uric acid); (vi) febrile neutropenia grade 3 or grade 4; (vii) prolonged
delay (>2 weeks) in initiation of cycle 2 because of treatment-related
toxicity; and (viii) any treatment-related toxicity that caused the
patient to discontinue treatment during cycle 1. Peripheral blood
MK-4830 RO pharmacokinetics and ADAs were summarized by
planned visit and time for each dose. ORR and DCR were assessed
in the full analysis set, which included patients with measurable disease
at baseline who received ≥1 dose of study treatment. The clinical data
cutoff date was July 10, 2020.
Availability of data and materials
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
(MSD), is committed to providing qualiﬁed scientiﬁc researchers
access to anonymized data and clinical study reports from the company’s clinical trials for the purpose of conducting legitimate scientiﬁc
research. MSD is also obligated to protect the rights and privacy of trial
participants and, as such, has a procedure in place for evaluating and
fulﬁlling requests for sharing company clinical trial data with qualiﬁed
external scientiﬁc researchers. The MSD data-sharing website (available at: http://engagezone.msd.com/ds_documentation.php) outlines
the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD subject
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matter experts to assess the scientiﬁc validity of the request and the
qualiﬁcations of the requestors. In line with data privacy legislation,
submitters of approved requests must enter into a standard datasharing agreement with MSD before data access is granted. Data will be
made available for request after product approval in the United States
and the European Union or after product development is discontinued. There are circumstances that may prevent MSD from sharing
requested data, including country or region-speciﬁc regulations. If the
request is declined, it will be communicated to the investigator. Access
to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by
the requestor and MSD subject matter experts; after approval of the
statistical analysis plan and execution of a data-sharing agreement,
MSD will either perform the proposed analyses and share the results
with the requestor or will construct biomarker covariates and add them
to a ﬁle with clinical data that is uploaded to an analysis portal so that
the requestor can perform the proposed analyses.

Results
Patients and baseline characteristics
From July 11, 2018 to July 10, 2020, 99 patients were screened
and 84 were treated in the dose-escalation phase of this study (MK4830 monotherapy, n ¼ 50; MK-4830 plus pembrolizumab, n ¼ 34;
Supplementary Fig. S1). Eighteen patients crossed over from the
monotherapy group to receive combination therapy upon radiological conﬁrmation of PD. The median age was 63 years (range,
31–83); most patients (56%) had previously received ≥3 lines of
therapy, and 23 patients (27%) had been previously treated with
immunotherapy, including anti–PD-1/PD-L1 therapy (Supplementary Table S1).
In the monotherapy group, patients were treated with MK-4830 at
the following doses: 3 mg (n ¼ 2), 10 mg (n ¼ 2), 30 mg (n ¼ 1), 100 mg
(n ¼ 7), 300 mg (n ¼ 8), 800 mg (n ¼ 15), and 1,600 mg (n ¼ 15). In the
combination group, all patients received pembrolizumab 200 mg plus
MK-4830 at the following doses: 100 mg (n ¼ 5), 300 mg (n ¼ 6),
800 mg (n ¼ 8), and 1,600 mg (n ¼ 15).
Median time from cycle 1, day 1 of treatment to data cutoff was
17 months (range, 11–24) in the monotherapy group and 13 months
(range, 11–18) in the combination group.
At the data cutoff, median treatment duration was 1 month
(range, 0–16) in the monotherapy group and 4 months (range,
0–15) in the combination group; 46 patients (PD, n ¼ 43; AE, n ¼ 2;
patient withdrawal, n ¼ 1) and 25 patients (PD, n ¼ 24; AE, n ¼ 1)
discontinued study treatment, respectively.
Safety
No DLTs were observed, and an MTD was not reached in either the
monotherapy or the combination therapy group. In the monotherapy
group, 50 patients (100%) experienced an AE (Table 1); the most
common (≥20%) were fatigue (40%), nausea (28%), decreased appetite
(22%), and diarrhea (20%; Table 1). Treatment-related AEs (TRAE) of
any grade occurred in 24 patients (48%; Table 1); 3 patients (6%)
experienced a total of 7 grade 3 or grade 4 events (fatigue, n ¼ 1;
increased AST, n ¼ 2; increased ALT, n ¼ 1; increased blood alkaline
phosphatase, n ¼ 1; increased blood pressure, n ¼ 1; increased gammaglutamyl transferase, n ¼ 1; Table 1). One patient (2%) discontinued
treatment because of a TRAE (increased AST, grade 2). Of the 52
patients treated with combination therapy (n ¼ 34 in part C; n ¼ 18
who crossed over from parts A and B), 48 (92%) experienced AEs
(Table 1); the most common (≥20%) were decreased appetite (27%),
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fatigue (27%), and vomiting (21%; Table 1). TRAEs of any grade
occurred in 28 patients (54%; Table 1); 4 patients (8%) experienced a
grade 3 or grade 4 event (fatigue, n ¼ 1; pneumonitis, n ¼ 1;
hyperglycemia, n ¼ 1; hypotension, n ¼ 1; Table 1). One patient
discontinued treatment because of a TRAE (pneumonitis). Four
patients (8%) in the combination group experienced a serious TRAE;
none led to discontinuation. No treatment-related deaths (grade 5
event) occurred in either treatment group.
Pharmacokinetics/pharmacodynamics
Serum levels of MK-4830 increased with increasing doses (3–
1,600 mg; Supplementary Fig. S2A). Increases in MK-4830 doses
(3–1,600 mg) resulted in dose-dependent increases in blood ILT4 RO
(Supplementary Fig. S2B). The initial MK-4830 monotherapy dose
escalation followed an ATD to minimize the number of patients
treated at potentially subtherapeutic doses of MK-4830. The 100 mg
starting dose for part B, which used the mTPI design with ≥3 patients
per dose level, was considered appropriate to ensure some therapeutic
beneﬁt based on an average blood percentage RO of ≥60% at MK-4830
Ctrough (Supplementary Fig. S2B). In part B, an average blood RO of
>80% was achieved at dose levels above 300 mg throughout the dosing
interval. In patients with available MK-4830 serum pharmacokinetic
and blood RO data (n ¼ 21), the average blood percentage RO was
96.4%  3.62% at the end of cycle 1, that is, cycle 2 predose (day 21
pharmacokinetics showed Ctrough ¼ 74.9  17.9 mg/mL) at the 800-mg
dose level; attempts to quantify tumor ILT4 RO from fresh tumor
biopsy samples were not successful. MK-4830 immunogenicity assessment is ongoing, and preliminary results suggest a low incidence of
ADAs (data not shown). For MK-4830, a preliminary recommended
phase 2 dose of 800 mg Q3W was selected on the basis of the entirety of
the data, which included achieving >95% average blood RO in parts B
and C of dose escalation.
Tumor response
Eleven of 84 patients with heavily pretreated advanced solid tumors
in the dose-escalation phase of the trial achieved an objective response.
One of 50 patients in the monotherapy group achieved a conﬁrmed
partial response (PR) for an ORR of 2% (Table 2); this patient had
high-grade serous ovarian cancer and disease progression on 7 previous chemotherapy treatments and received MK-4830 at the 800-mg
dose level. Another patient with ovarian cancer in the monotherapy
group completed 35 cycles of treatment and had a best overall response
of SD. Eight of 34 patients receiving combination therapy achieved a
conﬁrmed response (CR, n ¼ 1; PR, n ¼ 7) and 6 additional patients
had SD ≥6 months (per RECIST v1.1 by investigator review) for an
ORR of 24% and a DCR of 41% (Table 2; Supplementary Table S2).
One additional patient in the combination treatment group achieved
an unconﬁrmed PR. In the crossover group, 1 patient with MSI-high
colorectal cancer achieved a conﬁrmed PR. Ten patients with a variety
of recurrent advanced solid tumors [head and neck squamous cell
carcinoma (HNSCC), n ¼ 2; gastric cancer, n ¼ 2; colorectal cancer,
n ¼ 2; non–small cell lung cancer (NSCLC), n ¼ 1; dendritic sarcoma,
n ¼ 1; papillary thyroid, n ¼ 1; Merkel cell carcinoma, n ¼ 1] had
continued PRs at doses of MK-4830 100 mg (n ¼ 1), 300 mg (n ¼ 1),
800 mg (n ¼ 4), and 1,600 mg (n ¼ 4). A total of 51% of patients with
responses previously received ≥3 lines of therapy. In addition, 5 of 11
patients (45%) whose disease had previously progressed on an anti–
PD-1/PD-L1 alone or in combination with other agents achieved PR
with MK-4830 plus pembrolizumab. All responses were maintained
for ≥6 months (Fig. 2A and B; Supplementary Fig. S3). Reductions in
target lesion size of ≥30% were observed in the patient receiving
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Table 1. Summary of AEs.

AE, n (%)
Any-grade AE
Grade 3–5
Led to discontinuation
Serious
Serious and led to discontinuation
Led to deathb
Any-grade TRAE
Grade 3–5
Led to discontinuation
Serious
Serious and led to discontinuation
Led to death
Most common AEs (≥10% incidence)
AE, n (%)
Fatigue
Nausea
Decreased appetite
Diarrhea
Abdominal pain
Dyspnea
Arthralgia
Back pain
Constipation
Cough
Pneumonia
Vomiting
Pyrexia
Upper abdominal pain
Anemia
Dizziness
Headache
Peripheral edema
Hypothyroidism
Increased blood creatinine
Most common TRAEs (≥5% incidence)
Fatigue
Diarrhea
Arthralgia
Increased aspartate aminotransferase
Decreased appetite
Nausea
Pruritus
Vomiting
Hypothyroidism
Maculopapular rash

MK-4830
monotherapya
n ¼ 50

MK-4830 þ
pembrolizumaba
n ¼ 52

50 (100)
23 (46)
2 (4)
14 (28)
0
2 (4)
24 (48)
3 (6)
1 (2)
0
0
0

48 (92)
23 (44)
1 (2)
18 (35)
0
0
28 (54)
4 (8)
1 (2)
4 (8)
0
0

Any
20 (40)
14 (28)
11 (22)
10 (20)
8 (16)
8 (16)
7 (14)
7 (14)
7 (14)
7 (14)
7 (14)
7 (14)
6 (12)
5 (10)
5 (10)
5 (10)
5 (10)
1 (2)
2 (4)
2 (4)

Grade ≥3
4 (8)
0
1 (2)
0
2 (4)
3 (6)
0
0
0
0
4 (8)
0
0
0
1 (2)
0
0
0
0
0

Any
14 (27)
8 (15)
14 (27)
8 (15)
8 (15)
8 (15)
7 (13)
7 (13)
7 (13)
7 (13)
1 (2)
11 (21)
3 (6)
1 (2)
8 (15)
4 (8)
6 (12)
9 (17)
7 (13)
6 (12)

Grade ≥3
1 (2)
0
0
1 (2)
2 (4)
0
0
1 (2)
0
0
1 (2)
0
0
0
4 (8)
0
0
0
0
0

6 (12)
5 (10)
4 (8)
3 (6)
3 (6)
3 (6)
3 (6)
3 (6)
2 (4)
2 (4)

1 (2)
0
0
2 (4)
0
0
0
0
0
0

7 (13)
2 (4)
3 (6)
1 (2)
1 (2)
3 (6)
2 (4)
1 (2)
5 (10)
4 (8)

1 (2)
1 (2)
0
0
0
0
0
0
0
0

Abbreviations: AE, adverse event; TRAE, treatment-related adverse event.
a
AEs occurring before crossover are counted in the monotherapy column; AEs occurring after crossover are counted in the combination therapy column.
b
AEs leading to death were death (n ¼ 1) and tumor hemorrhage (n ¼ 1).

monotherapy and the 10 patients receiving combination therapy
(including those who crossed over; Fig. 2C and D).
Biomarker analysis
PD-L1
Of the 34 patients in the dose-escalation phase who received
combination therapy, 25 [6 responders (CR or PR), 19 nonresponders
(SD, PD, or missing, including 5 patients with SD and PFS of
≥6 months)] had evaluable PD-L1 status (Fig. 3A). A general trend
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toward higher tumor PD-L1 combined positive score (CPS) expression
was observed in responders. Two patients with conﬁrmed response
had a tumor PD-L1 CPS or a tumor proportion score of 0 (1 patient
with microsatellite stable gastric cancer and another with NSCLC; data
not shown).
TMB
Twenty-one patients [6 responders (CR or PR), 15 nonresponders
(SD, PD, or missing, including 5 patients with SD and PFS of
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Table 2. Summary of conﬁrmed tumor response per RECIST v1.1 by investigator assessment.

Conﬁrmed response, n (%)

MK-4830 monotherapy
n ¼ 50

MK-4830 þ pembrolizumab
n ¼ 34

Crossover to MK-4830 þ
pembrolizumab
n ¼ 18

ORR
CR
PR
SD
SD with PFS ≥6 months
PD
No RECIST assessmentd

1 (2)a
0
1 (2)
11 (22)
5 (1)
34 (68)
4 (8)

8 (24)b
1 (3)
7 (21)
9 (26)
6 (18)
16 (47)
1 (3)

1 (6)c
0
1 (6)
1 (6)
0
3 (17)
13 (72)e

Abbreviations: CR, complete response; ORR, objective response rate; PFS, progression-free survival; PR, partial response; RECIST v1.1, Response Evaluation Criteria in
Solid Tumors version 1.1; SD, stable disease.
a
Patient had high-grade serous ovarian cancer.
b
Patients had head and neck squamous cell carcinoma (n ¼ 2), gastric cancer (n ¼ 2), Merkel cell carcinoma (n ¼ 1), dendritic sarcoma (n ¼ 1), non–small cell lung
cancer (n ¼ 1), and papillary thyroid (n ¼ 1).
c
Patient had microsatellite-high colorectal cancer.
d
Includes patients who had the opportunity to have a postbaseline assessment based on the date of their ﬁrst dose but did not have any postbaseline assessment by
the data cutoff date.
e
Eleven patients have been evaluated by immune Response Evaluation Criteria in Solid Tumors.
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Figure 2.
Target lesion change over time (RECIST v1.1) in patients who received (A) MK-4830 monotherapy or (B) MK-4830 in combination with pembrolizumab. Best
percentage change from baseline in target lesion based on investigator assessment (RECIST v1.1) in patients who received (C) MK-4830 monotherapy or (D)
MK-4830 in combination with pembrolizumab. RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.
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Figure 3.
Association between response and (A) PD-L1 status, (B)
TMB status, and (C) TcellinfGEP score. AUROC, area
under the receiver operating characteristic; CI, conﬁdence interval; CPS, combined positive score; CR, complete response; NR, nonresponder; PD, progressive disease; PD-L1, programmed death ligand 1; PR, partial
response; R, responder; SD, stable disease; TcellinfGEP,
T-cell–inﬂamed gene expression proﬁle; TMB, tumor
mutational burden. (Continued on the following page.)
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≥6 months)] had evaluable TMB status. No trend toward higher TMB
status was observed in patients who responded to study treatment
(Fig. 3B).
TcellinfGEP
Twenty-four patients [6 responders (CR or PR), 18 nonresponders
(SD, PD, or missing, including 4 patients with SD and PFS of
≥6 months)] had evaluable TcellinfGEP scores. The distribution of
the TcellinfGEP score was higher in responders than in nonresponders
(Fig. 3C).
Myeloid-speciﬁc biomarkers
Gene expression correlation patterns for myeloid-speciﬁc biomarkers LILRB2 (ILT4), HLA-G, and mMDSC signature score
against PD-L1, TMB, and TcellinfGEP are shown in Fig. 4. The
correlation between LILRB2 and mMDSC signature score was
very strong, with a Spearman correlation of 0.95; both these
biomarkers showed moderate correlations with PD-L1 (Spearman
correlation r ¼ 0.31 and 0.37, respectively), low correlations with
TMB (Spearman correlation r ¼ 0.29 and 0.28, respectively), and
strong correlations with TcellinfGEP (Spearman correlation r ¼
0.74 and 0.78, respectively). HLA-G also showed moderate correlations with the mMDSC (Spearman correlation r ¼ 0.46),
LILRB2 (Spearman correlation r ¼ 0.48), and TcellinfGEP (Spearman correlation r ¼ 0.34) but little to no correlations with PD-L1
(Spearman correlation r ¼ 0.03) or TMB (Spearman correlation
r ¼ 0.17).
Given this high degree of correlation between TcellinfGEP with
mMDSC and LILRB2 levels, we were interested in assessing the
distribution of LILRB2, mMDSC, and HLA-G as they relate to
response after adjusting for the TcellinfGEP (Fig. 5). The distribution
of residual scores trended numerically lower for responders than for
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nonresponders, with an area under the receiver operating characteristic (AUROC) curve for discriminating objective response of <0.5 for
mMDSC and LILRB2; no trends were evident when using DCR as the
deﬁnition of response.
Additional biomarkers
There were no notable differences in baseline or on-treatment
circulating cytokine levels (IFNg, IL1b, IL2, IL4, IL6, IL8, IL10,
IL12p70, IL13, and TNFa) between responders and nonresponders.
No evidence of dose-dependent changes was observed among
monocytes, neutrophils, mMDSCs, PMN-MDSCs, early-stage
MDSCs, and T-cell activation in response to MK-4830 treatment,
either in monotherapy or combination therapy. Variable trends
with response were observed among the putative ILT4 ligands
(HLA-A, HLA-B, HLA-C, HLA-F, and HLA-G); it was unclear
whether any individual or combination could be useful as a biomarker for response with this small sample size.

Discussion
In this ﬁrst-in-human trial, the anti-ILT4 antibody MK-4830 was
administered to patients with recurrent advanced solid tumors who
previously received an average of three anticancer therapies. At doses
ranging from 3 to 1,600 mg Q3W, MK-4830 demonstrated an acceptable safety proﬁle when given as monotherapy and in combination
with pembrolizumab. No DLTs or treatment-related deaths were
observed, and an MTD was not reached. In the combination therapy
group, the rate of grade 3 or grade 4 TRAEs was 8% and the rate of allcause AEs leading to study discontinuation was 2%. Both the types of
TRAEs observed in the MK-4830 monotherapy group and the rate of
TRAEs observed in the combination group were similar to those of
previous studies with pembrolizumab monotherapy (23, 24). Serum
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Figure 4.
Correlation between myeloid-speciﬁc biomarkers and (A) PD-L1 status, (B) TMB status, (C) TcellinfGEP score, and (D) other myeloid-speciﬁc biomarkers. CPS,
combined positive score; CR, complete response; HLA-G, human leukocyte antigen G; LILRB2, leukocyte immunoglobulin-like receptor B2; mMDSC, monocytic
myeloid-derived suppressor cell; NR, nonresponder; PD, progressive disease; PD-L1, programmed death ligand 1; PR, partial response; R, responder; SD, stable
disease; TcellinfGEP, T-cell–inﬂamed gene expression proﬁle; TMB, tumor mutational burden.

MK-4830 concentration and membrane ILT4 RO increased in a dosedependent manner in both the monotherapy and the combination
therapy groups. At doses of 800 mg or higher, blood ILT4 RO
approached complete target saturation throughout the dosing interval
(Supplementary Fig. S2B). Low ADA rates for MK-4830 were consistent with ADA rates previously observed in pembrolizumab monotherapy studies (19, 25). For MK-4830, a preliminary recommended
phase 2 dose of 800 mg Q3W was selected on the basis of the total data.
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The overall safety proﬁle of combination therapy with MK-4830 and
pembrolizumab underscores its utility over more toxic therapies, such
as the addition of cytotoxic chemotherapy or radiotherapy, to overcome immune resistance.
Tumor responses were observed when MK-4830 was administered
as monotherapy and in combination with pembrolizumab; 45% of
patients achieved a PR with MK-4830 plus pembrolizumab after
previous disease progression on an anti–PD-1/PD-L1 alone or in
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Association between response and TcellinfGEP-adjusted
(A) LILRB2, (B) mMDSC, and (C) HLA-G. AUROC, area
under the receiver operating characteristic; CI,
conﬁdence interval; CR, complete response; HLA-G,
human leukocyte antigen G; LILRB2, leukocyte
immunoglobulin-like receptor B2; mMDSC, monocytic
myeloid-derived suppressor cell; NR, nonresponder; PD,
progressive disease; PR, partial response; R, responder;
SD, stable disease; TcellinfGEP, T-cell–inﬂamed gene
expression proﬁle. (Continued on the following page.)
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combination with other agents, and 3 responders previously had no
response to anti–PD-1/PD-L1 treatment or responded but then experienced disease progression. These ﬁndings suggest that MK-4830 is
active and may overcome a resistance mechanism to anti–PD-1/PD-L1
therapy.
Interestingly, preliminary biomarker data from this study suggest
that some responses occurred in patients whose tumors lacked molecular features typically associated with response to pembrolizumab
monotherapy, such as responders who had no detectable expression of
tumor tissue PD-L1. One such patient with a diagnosis of HER2–
negative microsatellite stable gastric cancer and disease progression
on three earlier treatments, including an anti–PD-1/PD-L1 antibody,
achieved a prolonged PR with MK-4830 plus pembrolizumab. A
second patient with NSCLC and disease progression on ﬁve earlier
treatments, including the PD-1 inhibitor nivolumab (which elicited no
response), achieved a conﬁrmed response with MK-4830 plus pembrolizumab and has continued on treatment for >6 months. Given that
both these patients had PD-L1–negative tumors and experienced
disease progression with other anti–PD-1/PD-L1 therapies, it is notable that they received lengthy therapeutic beneﬁt with MK-4830 plus
pembrolizumab. In addition to these clinical ﬁndings, it is noteworthy
that the data in our study showed a greater association between
TcellinfGEP and response by way of AUROC in patients treated with
MK-4830 plus pembrolizumab than was observed historically in the
pan-tumor setting with pembrolizumab monotherapy (21). Furthermore, the response rate among patients with TcellinfGEPlow (using the
ﬁrst tertile as a cutoff to deﬁne low and nonlow categories; refs. 20, 26)
was higher in this population [18% (3/17) for ORR] than it was in the
previously reported pan-tumor analysis [2% (1/45)] with pembrolizumab monotherapy (21). These ﬁndings suggest that targeting a

OF12 Clin Cancer Res; 2021

0.6

1–Specificity

myeloid-suppressive axis may increase the cytolytic activity of pembrolizumab at a lower threshold of T-cell inﬂammation. Sample sizes
in the present study were modest, however, and further data are needed
to verify such observations.
Ever since initial demonstrations that TcellinfGEP associates with
response to pembrolizumab monotherapy, a persistent puzzle has been
the existence of some highly inﬂamed tumors that do not respond to
anti–PD-1/PD-L1 therapy. Studying tumor microenviroment gene
expression variations beyond the TcellinfGEP is the subject of ongoing
research. A pooled analysis of a large number of single-arm pembrolizumab studies demonstrated the presence of resistance patterns for
monotherapy using signatures for stromal/epithelial–mesenchymal transition/TGF-beta–related expression, angiogenesis, and mMDSC (21).
Some of these resistance patterns may operate at different strengths in
different tumor types, and evaluation in larger randomized pembrolizumab monotherapy trials will be required for full understanding of the
role of these patterns on a tumor-speciﬁc basis.
Evaluation of mMDSC-related patterns and ILT4 levels is particularly complicated by their strong correlation to T-cell inﬂammation.
Our position is that the coincident effects of these two forms of
inﬂammation in a chronic setting are best understood by trying to
separate their relative contributions with the use of joint statistical
modeling. Without this, showing an association between the mMDSC
signature or ILT4 levels and tumor response with MK-4830 plus
pembrolizumab is difﬁcult to interpret because this association has
also been observed with pembrolizumab monotherapy. Joint modeling, which mathematically tests the respective independent components, shows a negative association between the TcellinfGEP–adjusted
mMDSC signature score and response in a large pan-tumor analysis (21). However, these pan-tumor ﬁndings suggested a subtle effect,
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and it was only with a large sample size (N ¼ 1,118) that this effect was
statistically signiﬁcant (21).
Anticipating the role of a biomarker developed in the pembrolizumab monotherapy setting when subsequently evaluated under
combination treatment requires careful thinking. The researcher
must ask whether trends noted in the pembrolizumab monotherapy
setting should become stronger or weaker in the context of an
effective combination of immunotherapies. Although our working
hypothesis is that the TcellinfGEP–adjusted mMDSC signature
score and ILT4 levels should no longer manifest as a biomarker
of resistence in the presence of an active anti-ILT4 plus anti–PD-1
combination, the data observed here are far from conclusive.
Furthermore, it is unclear whether focus should be on these
secondary patterns or on monitoring hallmark monotherapy biomarkers, such as PD-L1, TMB, and TcellinfGEP, to know whether
we are observing response rates at lower levels for these biomarkers
or overall improvements in their associations with clinical outcomes. These questions will continue to be assessed as further data
for this combination therapy accrue.
In the present study, response rates and some biomarker associations observed suggest that MK-4830 may overcome some myeloid
compartment–driven resistance mechanisms within the tumor microenvironment to enhance cytolytic T-cell responses in combination
with PD-1 blockade. This could occur by a synergistic mechanism
whereby MK-4830 blocks HLA-G binding to ILT4, which then
repolarizes monocytes to a derepressive phenotype, allowing T cells
to enter the tumor microenvironment and pembrolizumab to activate
the T cells to kill the tumor cells.
Limitations of this dose-escalation study include the small number
of patients, the lower dose levels (<800 mg) of MK-4830 received by
many patients, the heterogeneous nature of the tumor types in the
patient population, and the wide conﬁdence intervals. Nevertheless,
the intriguing data from this study support the further development of
MK-4830 in combination with pembrolizumab for patients with
advanced solid tumors and the continued investigation into the T-cell
and myeloid expression signatures. Expansion cohorts of this study
are ongoing in patients with varying tumor types, including pancreatic adenocarcinoma, HNSCC, NSCLC, renal cell carcinoma, gastric
cancer, glioblastoma, ovarian cancer, triple-negative breast cancer,
and mesothelioma.
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